Comparative Pharmacology
Head-to-head clinical analysis: DODEX versus HYDROXOCOBALAMIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DODEX versus HYDROXOCOBALAMIN.
DODEX vs HYDROXOCOBALAMIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydroxocobalamin is a synthetic form of vitamin B12, which acts as a cofactor for methionine synthase and methylmalonyl-CoA mutase, essential for DNA synthesis, myelin formation, and hematopoiesis.
Hydroxocobalamin is a precursor of methylcobalamin and adenosylcobalamin, which are essential cofactors for methionine synthase and methylmalonyl-CoA mutase. It facilitates the conversion of homocysteine to methionine and methylmalonyl-CoA to succinyl-CoA, and neutralizes cyanide by forming cyanocobalamin.
1 mg intramuscularly once every 7-10 days for maintenance; 1 mg intramuscularly once daily for 7 days for initial treatment.
1000 mcg intramuscularly once daily for 1 week, then weekly for 1 month, then monthly. For maintenance: 1000 mcg intramuscularly once monthly. Route: IM.
None Documented
None Documented
Terminal elimination half-life is approximately 6 days (range 4-10 days) in plasma; however, due to extensive tissue binding and enterohepatic recirculation, the pharmacodynamic half-life for correction of deficiency is about 1 year.
Terminal elimination half-life: ~26-31 days. After high-dose therapy, plasma levels decline more rapidly initially (α-phase half-life ~6 hours) due to distribution, followed by slow terminal elimination reflecting tissue release. Clinically, this supports monthly dosing for deficiency correction.
Primarily renal: ~50-80% of absorbed dose excreted unchanged in urine via glomerular filtration. Biliary/fecal excretion accounts for <10% as cyanocobalamin.
Primarily renal excretion (50-90% as unchanged drug). Biliary/fecal elimination accounts for <10%.
Category C
Category C
Vitamin B12 Supplement
Vitamin B12 Supplement